Merck & Coの空売り状況は、投資家がMerck & Coの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Merck & Co (NYSE:MRK) 株価情報, 空売り情報

Merck & Co

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Earnings

Equities

News

Pre-Market Outlook

Markets

Trading Ideas

投資家の恐怖指数は改善｜ダウは350ポイント以上の下落を記録

Merck & Co Inc

Marker Therapeutics Inc

Wednesday, the FDA approved Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40915575/fda-approves-mercks-keytruda-pembrolizumab-plus-pemetrexed-and-platinum-chemotherapy-as-first-line" rel="noreferrer noopener">malignant pleural mesothelioma (MPM).</a>
The approval marks the first indication for Keytruda in MPM in the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40896344/merckdaiichi-sankyo-partnered-lung-cancer-candidate-meets-primary-goal-in-late-stage-study" rel="noreferrer noopener">Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study</a>.
MPM&nbsp;is&nbsp;a rare, aggressive cancer that forms in the lining of the lungs and chest.
The approval is based on pivotal Phase 2/3 IND.227/KEYNOTE-483 trial data.
Keytruda plus chemotherapy demonstrated a statistically significant improvement in overall survival (OS), reducing the risk of death by 21% compared to chemotherapy alone.
Median OS was 17.3 months for Keytruda plus chemotherapy versus 16.1 months for chemotherapy alone.
Keytruda plus chemotherapy also significantly improved progression-free survival (PFS) versus chemotherapy alone.
The overall response rate (ORR) was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%), respectively.
Adverse reactions occurring in patients with MPM were generally similar to those in other patients receiving Keytruda in combination with pemetrexed and platinum chemotherapy.
In August, Merck discontinued two Keytruda <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40627374/merck-pulls-plug-on-two-keytruda-late-stage-studies-on-underwhelming-data" rel="noreferrer noopener">late-stage studies</a>.
<ul>
<li>Phase 3 KEYNOTE-867 trial evaluating Keytruda (pembrolizumab) in combination with stereotactic body radiotherapy for stage I or II non-small cell lung cancer, including those who are medically inoperable or <a href="https://www.benzinga.com/pressreleases/24/08/b40621006/merck-provides-update-on-phase-3-keynote-867-and-keynote-630-trials" target="_blank" rel="noreferrer noopener">have refused surgery</a>.</li>
<li>Phase 3 KEYNOTE-630 trial of Keytruda for the adjuvant treatment of patients with high-risk locally advanced cutaneous squamous cell carcinoma (cSCC) following surgery and radiation, based on the recommendation of an independent DMC.</li>
</ul>
Price Action: MRK stock is trading 0.04% higher at $118.34&nbsp;at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/m-a/24/09/40919923/consumer-giant-reckitt-seeks-help-from-investment-banks-to-evaluate-options-for-homecare-brands-baby" target="_blank" rel="noreferrer noopener">Consumer Giant Reckitt Seeks Help From Investment Banks To Evaluate Options For Homecare Brands, Baby Formula</a>.</li>
</ul>

Biotech

Large Cap

Health Care

General

Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer

Deep-pocketed investors have adopted a bullish approach towards Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRK usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Merck &amp; Co. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 75% leaning bullish and 0% bearish. Among these notable options, 4 are puts, totaling $160,474, and 4 are calls, amounting to $152,824.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $145.0 for Merck &amp; Co over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Merck &amp; Co stands at 3342.14, with a total volume reaching 7,571.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Merck &amp; Co, situated within the strike price corridor from $100.0 to $145.0, throughout the last 30 days.
<h3>Merck &amp; Co 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726680732_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$0.2</td>
<td>$0.01</td>
<td>$0.1</td>
<td>$100.00</td>
<td>$65.1K</td>
<td>8.5K</td>
<td>6.5K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.1</td>
<td>$5.05</td>
<td>$5.05</td>
<td>$140.00</td>
<td>$62.1K</td>
<td>195</td>
<td>125</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.53</td>
<td>$1.46</td>
<td>$1.46</td>
<td>$105.00</td>
<td>$42.3K</td>
<td>7.3K</td>
<td>290</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.7</td>
<td>$2.99</td>
<td>$3.5</td>
<td>$135.00</td>
<td>$35.0K</td>
<td>1.5K</td>
<td>100</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$2.65</td>
<td>$2.61</td>
<td>$2.65</td>
<td>$145.00</td>
<td>$28.0K</td>
<td>1</td>
<td>145</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Following our analysis of the options activities associated with Merck &amp; Co, we pivot to a closer look at the company's own performance.
<h3>Current Position of Merck &amp; Co</h3>
<ul>
<li>With a trading volume of 3,730,655, the price of MRK is up by 0.01%, reaching $118.3.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 36 days from now.</li>
</ul>
<h3>What The Experts Say On Merck &amp; Co</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $155.0.
<ul>
<li>An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $155. </li>
<li>An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $155. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Merck &amp; Co, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Behind the Scenes of Merck & Co's Latest Options Trends

The FDA Approves Merck's Keytruda In Combination With Pemetrexed And Platinum Chemotherapy, For The First-line Treatment Of Adult Patients With Unresectable Advanced Or Metastatic Malignant Pleural Mesothelioma

In today's fast-paced and competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies before making investment decisions. In this article, we will conduct a comprehensive industry comparison, evaluating Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) against its key competitors in the Pharmaceuticals industry. By examining key financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
<h3>Merck &amp; Co Background</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Merck &amp; Co Inc</td>
<td>21.84</td>
<td>6.86</td>
<td>4.81</td>
<td>13.0%</td>
<td>$7.45</td>
<td>$12.37</td>
<td>7.16%</td>
</tr>
<tr>
<td>Eli Lilly and Co</td>
<td>113.74</td>
<td>61.32</td>
<td>21.44</td>
<td>22.5%</td>
<td>$4.12</td>
<td>$9.13</td>
<td>35.98%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>45.94</td>
<td>36.50</td>
<td>16.01</td>
<td>18.97%</td>
<td>$35.74</td>
<td>$57.79</td>
<td>25.34%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>25.26</td>
<td>5.62</td>
<td>4.74</td>
<td>6.62%</td>
<td>$7.8</td>
<td>$15.58</td>
<td>4.31%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>38.37</td>
<td>6.20</td>
<td>5.03</td>
<td>5.01%</td>
<td>$4.12</td>
<td>$10.76</td>
<td>13.33%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>23.92</td>
<td>5.67</td>
<td>4.94</td>
<td>7.97%</td>
<td>$5.25</td>
<td>$9.7</td>
<td>9.6%</td>
</tr>
<tr>
<td>Sanofi SA</td>
<td>30.80</td>
<td>1.78</td>
<td>2.74</td>
<td>1.53%</td>
<td>$2.03</td>
<td>$7.97</td>
<td>6.53%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>14.71</td>
<td>4.71</td>
<td>1.91</td>
<td>8.32%</td>
<td>$2.31</td>
<td>$5.76</td>
<td>9.84%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>38.09</td>
<td>17.72</td>
<td>10</td>
<td>12.45%</td>
<td>$0.97</td>
<td>$1.69</td>
<td>8.3%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>44.38</td>
<td>0.85</td>
<td>1.50</td>
<td>1.26%</td>
<td>$388.51</td>
<td>$821.04</td>
<td>14.11%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>20.07</td>
<td>3.78</td>
<td>3.87</td>
<td>4.84%</td>
<td>$21.72</td>
<td>$46.34</td>
<td>13.87%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals PLC</td>
<td>18.57</td>
<td>1.80</td>
<td>1.96</td>
<td>4.52%</td>
<td>$0.36</td>
<td>$0.91</td>
<td>6.95%</td>
</tr>
<tr>
<td>Organon &amp; Co</td>
<td>5.38</td>
<td>37.33</td>
<td>0.85</td>
<td>203.12%</td>
<td>$0.43</td>
<td>$0.94</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>34.04</td>
<td>6.74</td>
<td>7.48</td>
<td>6.14%</td>
<td>$0.04</td>
<td>$0.16</td>
<td>39.15%</td>
</tr>
<tr>
<td>Prestige Consumer Healthcare Inc</td>
<td>18.01</td>
<td>2.17</td>
<td>3.32</td>
<td>2.94%</td>
<td>$0.08</td>
<td>$0.15</td>
<td>-4.36%</td>
</tr>
<tr>
<td>Average</td>
<td>33.66</td>
<td>13.73</td>
<td>6.13</td>
<td>21.87%</td>
<td>$33.82</td>
<td>$70.57</td>
<td>13.06%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>When closely examining Merck &amp; Co, the following trends emerge: 
<ul>
<li>
A Price to Earnings ratio of 21.84 significantly below the industry average by 0.65x suggests undervaluation. This can make the stock appealing for those seeking growth.
</li>
<li>
Considering a Price to Book ratio of 6.86, which is well below the industry average by 0.5x, the stock may be undervalued based on its book value compared to its peers.
</li>
<li>
With a relatively low Price to Sales ratio of 4.81, which is 0.78x the industry average, the stock might be considered undervalued based on sales performance.
</li>
<li>
The company has a lower Return on Equity (ROE) of 13.0%, which is 8.87% below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.
</li>
<li>
With lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.45 Billion, which is 0.22x below the industry average, the company may face lower profitability or financial challenges.
</li>
<li>
With lower gross profit of $12.37 Billion, which indicates 0.18x below the industry average, the company may experience lower revenue after accounting for production costs.
</li>
<li>
The company's revenue growth of 7.16% is significantly lower compared to the industry average of 13.06%. This indicates a potential fall in the company's sales performance.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726585251_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio indicates the proportion of debt and equity used by a company to finance its assets and operations.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When examining Merck &amp; Co in comparison to its top 4 peers with respect to the Debt-to-Equity ratio, the following information becomes apparent:
<ul>
<li>
Merck &amp; Co is in a relatively stronger financial position compared to its top 4 peers, as evidenced by its lower debt-to-equity ratio of 0.87.
</li>
<li>
This implies that the company relies less on debt financing and has a more favorable balance between debt and equity.
</li>
</ul>
<h3>Key Takeaways</h3>
For Merck &amp; Co in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to peers, indicating potential undervaluation. However, the low ROE, EBITDA, gross profit, and revenue growth suggest weaker financial performance relative to industry competitors. This may reflect challenges in generating profits and growth for Merck &amp; Co within the sector.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Competitor Analysis: Evaluating Merck &amp; Co And Competitors In Pharmaceuticals Industry

Tuesday, Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) released topline data from the&nbsp;HERTHENA-Lung02&nbsp;phase 3 trial of patritumab deruxtecan in patients with locally advanced or metastatic&nbsp;EGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40893317/patritumab-deruxtecan-demonstrated-statistically-significant-improvement-in-progression-free-survi" rel="noreferrer noopener">inhibitor (TKI) treatment</a>.
The study met its primary endpoint of progression-free survival (PFS), with patritumab deruxtecan demonstrating a statistically significant improvement versus platinum plus pemetrexed induction chemotherapy followed by pemetrexed maintenance chemotherapy.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40694793/despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs" rel="noreferrer noopener">Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs</a>.
Overall survival (OS) data were immature at the time of the analysis, and the trial will continue to assess OS, a secondary endpoint.
Patritumab deruxtecan is a specifically engineered potential first-in-class HER3-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>) and being jointly developed by Daiichi Sankyo and Merck.
The safety profile seen in HERTHENA-Lung02 was consistent with that observed for patritumab deruxtecan in previous lung cancer clinical trials, with no new safety signals identified.
The majority of interstitial lung disease (ILD) events were low-grade (grades 1 and 2). Two grade 5 ILD events were observed.
Recently,&nbsp;Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)&nbsp;released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China,&nbsp;sponsored by collaboration&nbsp;partner&nbsp;Akeso, Inc.
The trial evaluated monotherapy ivonescimab against Merck&#8217;s Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer whose tumors have <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40771038/summit-therapeutics-lung-cancer-candidate-surpasses-mercks-multi-billion-dollar-keytruda-cuts-ris" rel="noreferrer noopener">positive PD-L1 expression</a>.
Ivonescimab monotherapy demonstrated a statistically significant improvement in the trial&#8217;s primary endpoint, progression-free survival, compared to monotherapy pembrolizumab, achieving a hazard ratio of 0.51.
Price Action: MRK stock is up 0.39% at $118.42 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40895062/essilorluxottica-and-meta-platforms-double-down-on-smart-eyewear-details" target="_blank" rel="noreferrer noopener">EssilorLuxottica And Meta Platforms Double Down On Smart Eyewear: Details</a>.</li>
</ul>

DSNKY

SMMT

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study

The&nbsp;HERTHENA-Lung02&nbsp;phase 3 trial evaluating patritumab deruxtecan in patients with locally advanced or metastaticEGFR-mutated non-small cell lung cancer (NSCLC) who received prior EGFR tyrosine kinase inhibitor (TKI) treatment met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement versus platinum plus pemetrexed induction chemotherapy followed by pemetrexed maintenance chemotherapy.
Overall survival (OS) data were immature at the time of the analysis and the trial will continue to further assess OS, a secondary endpoint.

Daiichi Sankyo And Merck Report Patritumab Deruxtecan Showed Statistically Significant Progression-Free Survival Improvement In EGFR-Mutated Non-Small Cell Lung Cancer Population

8 analysts have shared their evaluations of Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.12, a high estimate of $155.00, and a low estimate of $125.00. This current average represents a 2.29% decrease from the previous average price target of $147.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1726513241_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Merck &amp; Co among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$142.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$125.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$142.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$134.00</td>
<td>$132.00</td>
</tr>
<tr>
<td>Louise Chen</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$155.00</td>
<td>$155.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Merck &amp; Co. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merck &amp; Co compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Merck &amp; Co's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Merck &amp; Co's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MRK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Merck &amp; Co analyst ratings.</a>
<h2>Unveiling the Story Behind Merck &amp; Co</h2>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
<h3>A Deep Dive into Merck &amp; Co's Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Merck &amp; Co's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.16% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Merck &amp; Co's net margin is impressive, surpassing industry averages. With a net margin of 33.86%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Merck &amp; Co's ROE excels beyond industry benchmarks, reaching 13.0%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Merck &amp; Co's ROA stands out, surpassing industry averages. With an impressive ROA of 4.99%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Merck &amp; Co's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.87.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

A Closer Look at 8 Analyst Recommendations For Merck & Co

Cantor Fitzgerald analyst Louise Chen reiterates Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) with a Overweight and maintains $155 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target

On Saturday, NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>)&nbsp;presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) for metastatic melanoma who were refractory to or had relapsed on prior <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40864700/nucana-presents-encouraging-data-on-nuc-7738-in-combination-with-pembrolizumab-in-pd-1-inhibitor-r" rel="noreferrer noopener">PD-1 inhibitor therapy</a>.
In this 12-patient cohort, most patients had received at least two prior lines of PD-1 inhibitor therapy.
Nine out of twelve (75%) achieved disease control, including two patients who achieved Partial Responses.
One of these patients, who had received two prior lines of PD-1 inhibitor-based therapy and had progressed on their latest treatment of ipilimumab plus nivolumab within two months, achieved a 55% reduction in tumor volume.
Seven of the 12 patients had a progression-free survival time of over five months.
Hugh Griffith, NuCana's Founder and CEO, said, "We are very excited to share these data on NUC-7738 in combination with pembrolizumab in PD-1 inhibitor refractory and resistant patients with melanoma. Outcomes in this patient population are very poor, with median progression-free survival of 2-3 months with the current standard of care, so we are very encouraged that the majority of patients who received this combination achieved a progression-free survival of more than five months."
In addition to achieving these encouraging efficacy signals, the combination of NUC-7738 and pembrolizumab had a favorable safety profile.
The company says NUC-7738 can sensitize PD-1-resistant tumors to rechallenge with PD-1 inhibitors due to its ability to target multiple aspects of the tumor microenvironment (TME) via the disruption of RNA polyadenylation and subsequent changes to gene expression in cancer cells.
Data from tumor biopsies obtained before and after NUC-7738-based treatment demonstrated increases in genes related to antigen presentation and T-cell activation.
In August, NuCana discontinued NuTide:323 study following a pre-planned initial analysis and recommendation from the NuTide:323&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40651009/nucana-stock-plunges-on-colorectal-combo-therapy-trial-setback-ends-mid-stage-study-after-disappo" rel="noreferrer noopener">Study Steering Committee</a>.
While there were prognostic imbalances favoring the control arm, the Steering Committee believed that the combination of NUC-3373 with leucovorin, irinotecan, and bevacizumab (NUFIRI+bev) was unlikely to achieve the study's primary objective of superior Progression-Free Survival compared to the control arm of 5-FU, leucovorin, irinotecan, and bevacizumab (FOLFIRI+bev) in&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/ncna" rel="noreferrer noopener">the final analysis</a>.
Price Action: NCNA stock is up 166.50% at $6.62 during the premarket session at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/40873852/exclusive-gauzy-to-showcase-ai-powered-driver-assistance-system-for-safer-commercial-trucks" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Gauzy To Showcase AI-Powered Driver Assistance System for Safer Commercial Trucks</a>.</li>
</ul>

Movers

NCNA

NuCana's Encouraging Data From Resistant Melanoma Treatment Provides Some Relief After Disappointing Colorectal Cancer Data, Stock Surges

<ul>
<li>Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024</li>
<li>In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA outperformance is largest in CPS ≥20 with 31.0% ORR (34.5% ORR including partial response after data cut-off) versus 18.5% ORR for KEYTRUDA</li>
<li>Efti in combination with KEYTRUDA led to a high durability of response of 17.5 months in patients with any PD-L1 expression and combination continues to have favourable safety profile</li>
<li>Statistically significant increase in absolute lymphocyte count biomarker seen in the efti in combination with KEYTRUDA arm shows efti's biological activity in a randomised setting
<ul>
<li>Based on the high unmet need and encouraging results to date, with Overall Survival expected in 2025, the path forward will be discussed with regulatory agencies</li>
</ul>
</li>
</ul>

IMMP

Immutep's Efti In Combination With MSD's KEYTRUDA Leads To Efficacy With Favourable Safety In First Line Head And Neck Cancer

<ul>
<li>In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or death by&nbsp;34%&nbsp;compared to TACE alone</li>
<li>Late-breaking first interim analysis results are being presented during a Presidential Symposium session at the European Society for Medical Oncology Congress 2024</li>
</ul>

ESALF

Reported Saturday, Merck And Eisai's Phase 3 LEAP-012 Trial OF KEYTRUDA-LENVIMA Combo Shows 34% Reduction In Progression For Advanced Liver Cancer

<ul>
<li>KEYNOTE-A18 is the first Phase 3 study of an immunotherapy in combination with CRT to demonstrate a statistically significant and clinically meaningful improvement in overall survival versus CRT alone in these patients</li>
<li>Results&nbsp;were selected for the official press briefing and presentation during a Presidential Symposium session at the European Society for Medical Oncology Congress 2024 and published simultaneously in&nbsp;The Lancet</li>
</ul>

Reported Saturday, Merck's KEYTRUDA Plus Chemoradiotherapy Slashes Mortality Risk By 33% In Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

<ul>
<li>KEYTRUDA is the first anti-PD-1/L1 therapy in combination with trastuzumab and chemotherapy to demonstrate a statistically significant improvement in OS in this patient population</li>
<li>Results from the final analysis of KEYNOTE-811 are being presented during a Proffered Paper Session at the European Society for Medical Oncology (ESMO) Congress 2024 and published simultaneously in the&nbsp;New England Journal of Medicine</li>
<li>In the U.S., KEYTRUDA, in combination with trastuzumab and chemotherapy, is indicated under accelerated approval for first-line treatment in the subset of this patient population whose tumors express PD-L1 (Combined Positive Score [CPS] &ge;1), based on prior KEYNOTE-811 results</li>
</ul>

Reported Saturday, Merck's KEYTRUDA Plus Trastuzumab and Chemotherapy Extends Survival In Advanced Gastric Cancer Or GEJ Adenocarcinoma

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to&nbsp;23.6%&nbsp;of patients treated with ipilimumab
For patients with advanced melanoma, these long-term follow-up data showed the 10-year OS rate for KEYTRUDA was&nbsp;34.0%&nbsp;versus&nbsp;23.6%&nbsp;for ipilimumab. KEYTRUDA demonstrated a sustained OS benefit, reducing the risk of death by&nbsp;29%&nbsp;(HR=0.71 [95%&nbsp;CI, 0.60-0.85]). At 10 years, KEYTRUDA more than doubled the median OS compared to ipilimumab (32.7 months versus 15.9 months).

Reported Sunday, Merck's KEYTRUDA Achieves Sustained 10-Year Survival Advantage Over Ipilimumab In Advanced Melanoma

Thursday,&nbsp;Moderna&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)&nbsp;unveiled key updates at its annual R&amp;D Day by reducing annual R&amp;D spending by $1.1 billion by 2027, enabling a focus on <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40834547/moderna-outlines-post-covid-roadmap-cuts-research-budget-forecasts-2025-sales-below-expectations" rel="noreferrer noopener">ten prioritized products</a>.
The company expects R&amp;D expenses to fall from $4.8 billion in 2024E to $3.6 billion—$3.8 billion in 2027.
The strategy, expanding its portfolio into oncology and rare diseases, positions Moderna to deliver ten product approvals within the next three years.
Oppenheimer downgraded Moderna stock from Outperform to Perform and <a target="_blank" href="https://www.benzinga.com/quote/MRNA/analyst-ratings" rel="noreferrer noopener">removed the price target</a>.
Oppenheimer analyst writes that with a restructured R&amp;D budget, Moderna&#8217;s non-respiratory assets will play a larger role in shaping the pipeline and face increased pressure to reach commercialization.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40754517/modernas-investigational-mpox-vaccine-more-effective-than-current-approved-shot-animal-study-show" rel="noreferrer noopener">Moderna&#8217;s Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows</a>.
RBC Capital Market decreased the price target from $90 to $75 while maintaining the Sector rating.
The analyst notes the COVID-19 vaccine maker pushed its breaking-even event by two years to 2028.
The analyst remains confident in Moderna&#8217;s cancer vaccine and the potential of its broader platform over the long term. However, near-term challenges continue to be seen, such as declining COVID-19 vaccination rates and the gradual uptake of the respiratory syncytial virus (RSV) vaccine.
Needham&#8217;s analyst highlights substantial commercial and competitive challenges in the respiratory vaccine market across all indications. Investors appear to view cytomegalovirus (CMV) as a less significant commercial opportunity, while the rare disease programs, including MMA and PA, are expected to have only modest peak sales potential, estimated at around $500 million.
The analyst says the INT Oncology program, developed in partnership with Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), offers the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39138772/moderna-merck-reveal-three-year-data-for-individualized-cancer-therapy-in-high-risk-melanoma-pati" rel="noreferrer noopener">most upside potential</a>. However, progress has been slow, and revenue from this program is unlikely to materialize before 2027 or later. Needham maintains the Hold rating.
William Blair notes that Moderna&#8217;s pattern of issuing high financial expectations, followed by lowered guidance, has negatively impacted the company&#8217;s stock.
Since cutting its 2024 revenue forecast during its second-quarter earnings 2024 call, the stock has <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40139012/moderna-stock-trading-lower-on-dismal-guidance-analysts-cuts-price-targets-noting-c" rel="noreferrer noopener">dropped approximately 40%</a>.
The analyst highlights that although Moderna has now pushed back its goal of breaking even to 2028, it will still need to double its revenue from the projected $3.0 billion-$3.5 billion in 2024 to $6.0 billion by 2028 to achieve breakeven along with reduced operating costs and streamlined COGS.
Piper Sandler reiterates the Overweight rating on Moderna but lowers the price target to $115 from $157.
Price Action: MRNA stock closed lower by 2.01% to $68.28 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40858554/chevron-takes-step-towards-greener-shipping-details" target="_blank" rel="noreferrer noopener">Chevron Takes Step Towards Greener Shipping: Details</a>.</li>
</ul>
Photo via <a href="https://commons.wikimedia.org/wiki/File:Moderna_COVID-19_vaccine_%282021%29_F.jpg">Wikimedia Commons</a>

Analyst Color

Downgrades

MRNA

Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target

Investors with a lot of money to spend have taken a bearish stance on Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRK, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Merck &amp; Co.
This isn't normal.
The overall sentiment of these big-money traders is split between 0% bullish and 100%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $223,103, and 4 are calls, for a total amount of $197,991.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $85.0 to $130.0 for Merck &amp; Co over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Merck &amp; Co's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Merck &amp; Co's whale trades within a strike price range from $85.0 to $130.0 in the last 30 days. 
<h3>Merck &amp; Co 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726256140_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$0.84</td>
<td>$0.82</td>
<td>$0.82</td>
<td>$114.00</td>
<td>$108.6K</td>
<td>1.1K</td>
<td>1.3K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$32.2</td>
<td>$32.0</td>
<td>$32.0</td>
<td>$85.00</td>
<td>$92.8K</td>
<td>136</td>
<td>29</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$0.96</td>
<td>$0.79</td>
<td>$0.96</td>
<td>$114.00</td>
<td>$54.0K</td>
<td>1.1K</td>
<td>3.0K</td>
</tr>
<tr>
<td>MRK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.72</td>
<td>$2.62</td>
<td>$2.61</td>
<td>$125.00</td>
<td>$44.3K</td>
<td>6.4K</td>
<td>186</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$0.99</td>
<td>$0.95</td>
<td>$0.99</td>
<td>$114.00</td>
<td>$32.5K</td>
<td>1.1K</td>
<td>4.3K</td>
</tr>
</tbody>
</table>

<h3>About Merck &amp; Co</h3>
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Following our analysis of the options activities associated with Merck &amp; Co, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Merck &amp; Co</h3>
<ul>
<li>Currently trading with a volume of 4,446,595, the MRK's price is down by -0.01%, now at $115.23. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 41 days.</li>
</ul>
<h3>Expert Opinions on Merck &amp; Co</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $155.0.
<ul>
<li>Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $155.</li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Merck &amp; Co with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Merck & Co Unusual Options Activity

Health Canada Has Approved Merck's Keytruda (Pembrolizumab) For Adult And Pediatric Patients With Unresectable Or Metastatic Microsatellite Instability-high Or Mismatch Repair Deficient Solid Tumors Progressed Following Prior Treatment And Who Have No Satisfactory Alternative Treatment Options

Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, today announced positive top-line results from its pivotal Phase 3 trial (V503-064) evaluating the company's 9-valent Human Papillomavirus (HPV) vaccine, GARDASIL&#xAE;9 (Human Papillomavirus 9-valent Vaccine, Recombinant) in Japanese males ages 16 to 26 years. The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9 reduced the combined incidence of anogenital persistent infection caused by 9 types of HPV compared with a placebo.
"A decade after the first approval of GARDASIL9, Merck continues to evaluate this important vaccine in additional patient populations and remains committed to helping prevent certain HPV-related cancers through broad and equitable access globally," said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. "These data build on the clinical efficacy of GARDASIL 9 for the prevention of persistent infection in males and can potentially make a significant impact in addressing the global burden of certain HPV-related cancers and diseases."
Merck plans to share these data with regulatory authorities in Japan and other countries around the world to support licensure for use in males. The full results also will be presented at an upcoming scientific congress. The clinical development program evaluating GARDASIL 9 in males also includes an ongoing confirmatory Phase 3 trial evaluating efficacy in preventing HPV oral persistent infection to support effectiveness against HPV-related oropharyngeal and other head and neck cancers (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04199689%3Fterm%3DV503-049%26rank%3D1&amp;esheet=54120502&amp;newsitemid=20240911570329&amp;lan=en-US&amp;anchor=NCT04199689&amp;index=1&amp;md5=0539e685f07f343a7777332e1fe0c9ae">NCT04199689</a>).

Government

Regulations

Merck's GARDASIL 9 Meets Key Endpoints in Japanese Male HPV Trial

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 150 points on Monday.
Shares of Methanex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEOH#NASDAQ">MEOH</a>) fell sharply in today's <a href="https://www.benzinga.com/markets/equities/24/09/40769930/methanex-to-buy-ocis-international-methanol-business-for-2-05b-details">pre-market trading.</a>
Methanex disclosed that it has entered into a definitive agreement to acquire OCI Global‘s international methanol business for $2.05 billion.
Methanex shares tumbled 6.3% to $39.79 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>C4 Therapeutics, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCCC#NASDAQ">CCCC</a>) shares dipped 17% to $4.48 in pre-market trading. C4 Therapeutics will reveal preliminary CFT1946 monotherapy Phase 1 clinical data at ESMO Congress 2024.</li>
<li>Lotus Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>) shares fell 5.4% to $4.90 in pre-market trading after gaining around 6% on Friday.</li>
<li>Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) fell 4.8% to $112.23 in pre-market trading. Daiichi Sankyo and Merck&#8217;s Ifinatamab Deruxtecan showed response rates in extensive-stage small cell lung cancer in Phase 2 IDeate-Lung01 trial.</li>
<li>Mercer International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MERC#NASDAQ">MERC</a>) shares declined 3.2% to $5.50 in pre-market trading. Adient will replace Mercer International in the S&amp;P SmallCap 600.</li>
<li>Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) shares fell 3.1% to $12.68 in pre-market trading.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) fell 2.3% to $13.97 in pre-market trading after gaining over 4% on Friday.</li>
<li>Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares slipped 2.3% to $7.34 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40767657/s-p-500-records-largest-weekly-decline-since-march-2023-as-nvidia-google-tumble-fear-greed-index">S&amp;P 500 Records Largest Weekly Decline Since March 2023 As Nvidia, Google Tumble: Fear &amp; Greed Index Moves To &#8216;Fear&#8217; Zone</a></li>
</ul>

CCCC

MEOH

MERC

Methanex, Merck And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Sunday, Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/b40764157/ivonescimab-monotherapy-reduced-the-risk-of-disease-progression-or-death-by-49-compared-to-pembrol" rel="noreferrer noopener">sponsored by collaboration</a> partner Akeso, Inc.
The data was presented at the International Association for the Study of Lung Cancer&#8217;s 2024 World Conference on Lung Cancer.
The trial evaluated monotherapy ivonescimab against monotherapy Merck &amp; Co Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Keytruda (pembrolizumab) in patients with locally advanced or metastatic non-small cell lung cancer whose tumors have positive PD-L1 expression.
Ivonescimab monotherapy demonstrated a statistically significant improvement in the trial&#8217;s primary endpoint, progression-free survival, compared to monotherapy pembrolizumab, achieving a hazard ratio (HR) of 0.51.
Ivonescimab slashed the risk of disease progression or death by 49% compared with Merck&#8217;s Keytruda.
Compared with Keytruda, ivonescimab extended the median progression-free survival, reaching 11.14 months vs. 5.82 months for Keytruda.
A clinically meaningful benefit was demonstrated across clinical subgroups, including those with PD-L1 low and high expression, squamous and non-squamous histologies, and other high-risk patients.
The overall response rate (ORR) and the disease control rate (DCR) were higher in patients treated with ivonescimab than those treated with pembrolizumab. ORR was observed at 50% vs. 38.5, and DCR was 89.9% versus 70.5%, respectively.
Overall survival data was not yet mature at the time of the data cutoff and will be evaluated in the future.
Summit plans to initiate HARMONi-7 in early 2025, a multi-regional Phase 3 trial to compare ivonescimab monotherapy to pembrolizumab monotherapy in patients with metastatic NSCLC whose tumors have high PD-L1 expression.
The company also shared data from the Phase 2 trial of ivonescimab alone or combined with chemotherapy in resectable non-small cell lung cancer, conducted in Chinese patients.
The study is designed to assess patients receiving either ivonescimab monotherapy or ivonescimab plus chemotherapy before surgical resection and then ivonescimab monotherapy after surgery.&nbsp;
Of the 39 patients who received ivonescimab plus chemotherapy in the neo-adjuvant stage and completed surgery, 71.8% experienced a major pathological response, and 43.6% experienced a pathological complete response.
In the 49 patients enrolled in this cohort, median event-free survival (EFS) was not yet reached after 8.9 months of median follow-up time; the 12-month EFS rate was 80.3%.
The safety profile was manageable: of the 49 patients who received ivonescimab plus chemotherapy in the neoadjuvant setting.
There were no TRAEs leading to delayed or canceled surgery or the death of a patient.
Price Action: SMMT stock is up 30.4% at $16.00 during the premarket session at last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/40754517/modernas-investigational-mpox-vaccine-more-effective-than-current-approved-shot-animal-study-show" target="_blank" rel="noreferrer noopener">Moderna&#8217;s Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows</a>.</li>
</ul>

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half

BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC

Merck, Daiichi post late-stage trial win for novel lung cancer therapy

BioNTech raised to buy at Jefferies on new cancer drug

Merck's Keytruda label expanded in the U.S. for mesothelioma

ESMO 2024 Roundup: A Lot Of Stumbles, But There Are New Signs Of Life

Merck & Co., Inc. (MRK) Bank of America Global Healthcare Conference (Transcript)

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report). The associated p...

Merck & Company Buy Rating Justified by Keytruda's Performance and Gardasil's Market Potential

3 Fantastic Dividend Stocks To Avoid The 'Lost Decade'

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

AMGN

BAYRY

BAYZF

BNTX

BYSI

DSKYF

EXEL

ROIV

TNGX

Screenshot 2023-07-10 at 5.56.06 PM

GNPX

Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate

Press Releases

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma

Merck's KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma

Ten-Year Data for Merck's KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024

PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch

Could Nuvectis Pharma be the Next Summit Therapeutics? A New Report Highlights NXP900's Approach to NSCLC Treatment

Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)

NVCT

TYO:4568

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Merck & Co

空売り

Merck & Co (NYSE:MRK) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル